Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
about
Exosomes as a tumor immune escape mechanism: possible therapeutic implicationsFocus on adoptive T cell transfer trials in melanomaAdoptive immunotherapy for cancer: building on successSpecific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsPhenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcomaAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookAllogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factorsSleeping beauty system to redirect T-cell specificity for human applications.Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposureFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaEx vivo expansion of human CD8+ T cells using autologous CD4+ T cell helpProgram death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapyModulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapyTreatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cellsProtection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory.Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment.Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationChimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapyLymphocyte therapy of renal cell carcinoma.Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion.Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scaleEffects of the tumor microenvironment on the efficacy of tumor immunotherapy.IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.Immune correlates of melanoma survival in adoptive cell therapy.Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.Targeted regulation of a lymphocyte-endothelial-interleukin-6 axis by thermal stress.
P2860
Q21245472-43B21FDD-A6EF-4767-8D78-634D66B5BF8AQ21328679-F0BEF1E2-BD8C-4BC6-BBEA-FA68FEA3F16BQ24546258-B8B4E273-2E3E-4C30-926D-E8AAA9484369Q24598792-B343CCEC-615D-4B98-8617-800C9B4C81B5Q24814867-D8C926E9-B4FE-47EB-A2F8-A8BEF4B45167Q27004178-EA31754A-ACE3-4FE3-911D-15E88B7CBA29Q28652288-E9DE1B77-29C7-402E-AAC8-1BC245132DEAQ30535187-BF51571F-24F1-4ED2-988D-82DF88E06F65Q33261122-FDBC08B2-8B69-4E39-B804-F168CCB1F956Q33413155-4CD1514B-C268-402E-9383-788650F1F82AQ33530527-AB3C018B-A999-468B-9D5D-C80D111288D5Q33839836-1F64AF75-4EE2-4BC0-90BD-EDD3082E5DF5Q33849560-453A4CED-D944-4317-AC89-8067153F79BCQ33855420-85CD9AB7-677B-47C7-A1D9-C9106BF7D3D7Q33993999-60039689-FEFC-4A23-A8E0-92F2FF86F9D1Q34111789-CC1D8176-15A8-48CA-A295-B4F4A224D2AFQ34141754-F67712A3-50AA-465E-942C-D843F4F7E5BDQ34193534-7DF9CD99-474A-41DE-9B30-B6C55E54476DQ34216825-7E08D91A-4F1B-4622-B9FD-908991FBF47CQ34299986-D96A4466-7922-42DC-B47F-727C74E404FEQ34557953-A20E5934-0A24-437D-8C41-BD8D75CDF101Q34592273-01713DDB-8FE2-424B-8459-522D3AF0CA24Q34656292-ADA61BA1-0C68-4DAF-A8CF-6331AA59C042Q34823783-A682A767-4981-4E66-9BCC-FE37E1A1BEA3Q34936175-3EC87DC6-1CB0-45B0-812C-68F9FADBCB0DQ34985537-57A9802A-ED04-4743-A24C-F59C6E0179FDQ35130794-470FD3F8-D76A-4358-89BA-244A08E8A377Q35207523-E473E818-E643-4A40-A14E-2EC2EDDDE694Q35860034-4C5D1B7F-DAF2-4F2E-834D-233ABCFE7EA5Q35891651-8FB3D160-5711-45F6-9436-D320908935DCQ35980893-3DE32251-2591-4901-8149-31817D22F23FQ36107158-BF0518DE-E139-4719-ACA7-F5A7EFD718AEQ36334899-259AFF57-07AE-43B3-A6AB-9475924C3C5CQ36351988-B1DA312A-887F-443D-A70A-3D17D2239486Q36475411-4F3362E8-B645-4B0B-B3CA-BD552CB8731CQ36569004-4070F827-C5D8-4B18-BA32-3ADBB530509AQ36677310-FA260138-623F-4B1D-A04E-2F38DEA63E14Q36694896-5C0CE493-83AE-488C-83A9-A06251352BF1Q37002020-6C58AEBC-91AA-49F5-A1BE-596E00E9E013Q37063499-0D9502AB-FEBB-4D32-A268-14264122E635
P2860
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Survival, persistence, and pro ...... ociated with tumor regression.
@ast
Survival, persistence, and pro ...... ociated with tumor regression.
@en
type
label
Survival, persistence, and pro ...... ociated with tumor regression.
@ast
Survival, persistence, and pro ...... ociated with tumor regression.
@en
prefLabel
Survival, persistence, and pro ...... ociated with tumor regression.
@ast
Survival, persistence, and pro ...... ociated with tumor regression.
@en
P2093
P2860
P1476
Survival, persistence, and pro ...... ociated with tumor regression.
@en
P2093
Hung T Khong
Jianping Huang
Mark E Dudley
Mona El-Gamil
Paul F Robbins
Steven A Rosenberg
P2860
P304
P356
10.1097/01.CJI.0000158855.92792.7A
P577
2005-05-01T00:00:00Z